DK2307376T3 - Hidtil ukendte phenylamino-isonikotinamidforbindelser - Google Patents
Hidtil ukendte phenylamino-isonikotinamidforbindelser Download PDFInfo
- Publication number
- DK2307376T3 DK2307376T3 DK09790842.0T DK09790842T DK2307376T3 DK 2307376 T3 DK2307376 T3 DK 2307376T3 DK 09790842 T DK09790842 T DK 09790842T DK 2307376 T3 DK2307376 T3 DK 2307376T3
- Authority
- DK
- Denmark
- Prior art keywords
- hydrogen
- hal
- pharmaceutically acceptable
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (10)
1. Forbindelse med formel (II)
og farmaceutisk acceptable salte, eller solvater deraf, hvor: R1 er hydrogen, methyl, ethyl, n-propyl, i-propyl, SH eller Hal, R2 er hydrogen, methoxy, ethoxy, acetylen, cyano, SH eller Hal, R3, R4 er uafhængigt valgt blandt hydrogen, SH eller Hal, og Hal er F, Cl, Br eller I.
2. Forbindelsen ifølge krav 1, hvor de radikaler der ikke er angivet i større detalje har betydningen indikeret forformlen (II) ifølge krav 1, men i hvilken i underformel IA R1 er Hal, methyl eller ethyl, R2 er hydrogen, Hal, methoxy eller acetylen, R3 er hydrogen eller Hal, R4 er hydrogen eller Hal, Hal er F, Cl, Br eller I, i underformel IB R1 er Hal, R2 er hydrogen eller Hal, R3 er hydrogen eller Hal, R4 er hydrogen eller Hal, Hal er F, Cl, Br eller I, i underformel IC R1 er F, Cl, methyl eller ethyl, R2 er hydrogen, I, Br, methoxy eller acetylen, R3 er hydrogen eller Hal, R4 er hydrogen eller Hal, Hal er F, Cl, Br eller I, 5 i underformel ID R1 er F, Cl, methyl eller ethyl, R2 er hydrogen, I, Br, methoxy eller acetylen, R3 er hydrogen eller F, R4 er hydrogen eller Cl 10 i underformel IE R1 er F eller Cl, R2 er I eller Br, R3 er hydrogen eller F, R4 er hydrogen eller Cl 15 i underformel IF R1 er F eller Cl, R2 er I eller Br, R3 er hydrogen eller F, R4 er hydrogen eller Cl, 20 i underformel IG R1 er F eller Cl, R2 er I eller Br, R3 er hydrogen, R4 er hydrogen, 25 og i underformel IH R1 er F, R2 er I, R3 er hydrogen eller F, R4 er hydrogen eller Cl, 30 og farmaceutisk acceptable salte eller solvater deraf.
3. Forbindelsen ifølge krav 1, hvor forbindelsen er valgt fra gruppen bestående af:
og farmaceutisk acceptable salte eller solvater deraf.
4. Farmaceutisk sammensætning omfattende en forbindelse ifølge et hvilket som helst af kravene 1 til 3, eller et farmaceutisk acceptabelt salt eller solvat deraf, som aktiv bestanddel, sammen med en farmaceutisk acceptabel bærer.
5. Forbindelse ifølge et hvilket som helst af kravene 1 til 3, eller et farmaceutisk acceptabelt salt eller solvat deraf, til anvendelse som medikament.
6. Forbindelse ifølge et hvilket som helst af kravene 1 til 3, eller et farmaceutisk acceptabelt salt eller solvat deraf, til anvendelse i behandlingen af hyperproliferative sygdomme relateret til hyperaktiviteten af MEK såvel som sygdomme moduleret gennem MEK-kaskaden hos pattedyr
7. Forbindelsen ifølge krav 6, eller et farmaceutisk acceptabelt salt eller solvat deraf, til anvendelse ifølge krav 6, hvor sygdommen er valgt fra gruppen bestående af cancer, inflammation, pankreatitis eller blæresygdom, smerte, benign hyperplasi af huden, restenose, prostata, sygdomme relateret til vaskulogenese eller angiogenese, tumor angiogenese, hudsygdomme valgt fra psoriasis, eksem, og skleroderma, diabetes, diabetisk retinopati, retinopati hos for tidligt fødte, alders-relateret makulær degenerering, hæmangiom, gliom, melanom og Kaposi's sarcom.
8. Forbindelsen ifølge krav 7, eller et farmaceutisk acceptabelt salt, eller solvat deraf, til anvendelse ifølge krav 7, hvor sygdommen er cancer.
9. Forbindelsen ifølge krav 8, eller et farmaceutisk acceptabelt salt, eller solvat deraf, til anvendelse ifølge krav 8 hvor canceren er hjerne-, lunge-, skvamøs celle-, blære-, mave-, bugspytkirtel-, bryst-, hoved-, hals-, blære-, nyre-, æggestok-, prostata-, colorektal-, spiserør-, testikel-, gynækologisk- eller skjoldbruskkirtelcancer, melanom, myelogen leukæmi, multipel melanom, kronisk myelogen leukæmi eller myeloid celleleukæmi.
10. Sæt (kit) bestående af separate pakker af en effektiv mængde af en forbindelse ifølge et hvilket som helst af kravene 1 til 3 eller et farmaceutisk acceptabelt salt eller solvat deraf, og en effektiv mængde af en yderligere medikament-aktiv bestanddel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13785808P | 2008-08-04 | 2008-08-04 | |
PCT/US2009/051817 WO2010017051A1 (en) | 2008-08-04 | 2009-07-27 | Novel phenylamino isonicotinamide compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2307376T3 true DK2307376T3 (da) | 2016-01-11 |
Family
ID=41078311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09790842.0T DK2307376T3 (da) | 2008-08-04 | 2009-07-27 | Hidtil ukendte phenylamino-isonikotinamidforbindelser |
Country Status (29)
Country | Link |
---|---|
US (2) | US8404725B2 (da) |
EP (1) | EP2307376B1 (da) |
JP (1) | JP2011529963A (da) |
KR (1) | KR101651700B1 (da) |
CN (1) | CN102099336B (da) |
AR (1) | AR072904A1 (da) |
AU (1) | AU2009279940B2 (da) |
BR (1) | BRPI0916566B8 (da) |
CA (1) | CA2732828C (da) |
CL (1) | CL2011000258A1 (da) |
CO (1) | CO6341612A2 (da) |
DK (1) | DK2307376T3 (da) |
EA (1) | EA018539B1 (da) |
EC (1) | ECSP11010867A (da) |
ES (1) | ES2560878T3 (da) |
HK (1) | HK1159097A1 (da) |
HR (1) | HRP20160044T1 (da) |
HU (1) | HUE027223T2 (da) |
IL (1) | IL210937A (da) |
MX (1) | MX2011001127A (da) |
MY (1) | MY151342A (da) |
NZ (1) | NZ591498A (da) |
PE (1) | PE20110665A1 (da) |
PL (1) | PL2307376T3 (da) |
PT (1) | PT2307376E (da) |
SI (1) | SI2307376T1 (da) |
UA (1) | UA107183C2 (da) |
WO (1) | WO2010017051A1 (da) |
ZA (1) | ZA201101661B (da) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201201671A1 (ru) * | 2010-07-01 | 2013-08-30 | Мерк Патент Гмбх | Способ получения цис-1,2-диолов в килограммовом масштабе |
EP2632899A1 (en) * | 2010-10-29 | 2013-09-04 | Bayer Intellectual Property GmbH | Substituted phenoxypyridines |
HUE035751T2 (hu) | 2011-09-02 | 2018-08-28 | Novartis Ag | Gyulladásgátló szubsztituált ciklobuténdion vegyület kolinsó |
WO2015018421A1 (en) | 2013-08-07 | 2015-02-12 | Rigshospitalet Copenhagen University Hospital | Antibodies, compounds and derivatives thereof for use in the treatment of male infertility |
CN107108561B (zh) | 2014-11-20 | 2020-08-28 | 默克专利有限公司 | 用作irak抑制剂的杂芳基化合物及其用途 |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
CN106632021A (zh) * | 2016-09-27 | 2017-05-10 | 中国药科大学 | 2‑取代异烟酸类化合物、其制备方法及其用途 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
WO1999001426A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
EP0993437B1 (en) | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
YU49401A (sh) | 1999-01-13 | 2004-07-15 | Warner-Lambert Company | Benzoheterocikli i njihova upotreba kao inhibitori mek |
ATE311363T1 (de) | 1999-01-13 | 2005-12-15 | Warner Lambert Co | Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren |
ES2252996T3 (es) | 1999-01-13 | 2006-05-16 | Warner-Lambert Company Llc | Derivados de bencenosulfonamida y su uso como inhibidores de mek. |
JP2002534446A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | 4′ヘテロアリールジアリールアミン |
SK9822001A3 (en) | 1999-01-13 | 2002-08-06 | Warner Lambert Co | 1-heterocycle substituted diarylamines, pharmaceutical compositions based thereon and their use in therapy |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
CA2403017A1 (en) | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
GEP20053496B (en) | 2000-07-19 | 2005-04-25 | Warner Lambert Co | Oxygenated Esters of 4-Iodo Phenylamino Benzhydroxamic Acids |
NZ535158A (en) | 2002-03-13 | 2007-06-29 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as MEK inhibitors |
AU2003220202A1 (en) | 2002-03-13 | 2003-09-29 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
JP5214971B2 (ja) * | 2004-10-20 | 2013-06-19 | メルク セローノ ソシエテ アノニム | 3−アリルアミノピペリジン誘導体 |
WO2007121269A2 (en) | 2006-04-11 | 2007-10-25 | Ardea Biosciences, Inc. | N-aryl-n'alkyl sulfamides as mek inhibitors |
JP5269762B2 (ja) | 2006-04-18 | 2013-08-21 | アーディア・バイオサイエンシーズ・インコーポレイテッド | Mek阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド |
CN101605540A (zh) | 2006-12-14 | 2009-12-16 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
-
2009
- 2009-07-27 HU HUE09790842A patent/HUE027223T2/en unknown
- 2009-07-27 NZ NZ591498A patent/NZ591498A/xx unknown
- 2009-07-27 US US13/057,052 patent/US8404725B2/en active Active
- 2009-07-27 AU AU2009279940A patent/AU2009279940B2/en active Active
- 2009-07-27 DK DK09790842.0T patent/DK2307376T3/da active
- 2009-07-27 CN CN200980128453XA patent/CN102099336B/zh active Active
- 2009-07-27 KR KR1020117005066A patent/KR101651700B1/ko active IP Right Grant
- 2009-07-27 PE PE2011000115A patent/PE20110665A1/es not_active Application Discontinuation
- 2009-07-27 CA CA2732828A patent/CA2732828C/en active Active
- 2009-07-27 WO PCT/US2009/051817 patent/WO2010017051A1/en active Application Filing
- 2009-07-27 PT PT97908420T patent/PT2307376E/pt unknown
- 2009-07-27 JP JP2011522112A patent/JP2011529963A/ja active Pending
- 2009-07-27 SI SI200931359T patent/SI2307376T1/sl unknown
- 2009-07-27 UA UAA201102396A patent/UA107183C2/ru unknown
- 2009-07-27 EA EA201100296A patent/EA018539B1/ru not_active IP Right Cessation
- 2009-07-27 EP EP09790842.0A patent/EP2307376B1/en active Active
- 2009-07-27 MX MX2011001127A patent/MX2011001127A/es active IP Right Grant
- 2009-07-27 MY MYPI20110408 patent/MY151342A/en unknown
- 2009-07-27 BR BRPI0916566A patent/BRPI0916566B8/pt active IP Right Grant
- 2009-07-27 ES ES09790842.0T patent/ES2560878T3/es active Active
- 2009-07-27 PL PL09790842T patent/PL2307376T3/pl unknown
- 2009-08-04 AR ARP090102980A patent/AR072904A1/es active IP Right Grant
-
2011
- 2011-01-27 IL IL210937A patent/IL210937A/en active IP Right Grant
- 2011-02-02 CO CO11011675A patent/CO6341612A2/es active IP Right Grant
- 2011-02-04 CL CL2011000258A patent/CL2011000258A1/es unknown
- 2011-03-03 EC EC2011010867A patent/ECSP11010867A/es unknown
- 2011-03-03 ZA ZA2011/01661A patent/ZA201101661B/en unknown
- 2011-12-14 HK HK11113513.8A patent/HK1159097A1/xx unknown
-
2013
- 2013-03-05 US US13/785,120 patent/US8889719B2/en active Active
-
2016
- 2016-01-14 HR HRP20160044TT patent/HRP20160044T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2307376T3 (da) | Hidtil ukendte phenylamino-isonikotinamidforbindelser | |
US20070293544A1 (en) | Novel 4-Arylamino Pyridone Derivatives as Mek Inhibitors for the Treatment of Hyper-Proliferative Disorders | |
EP1828184B1 (en) | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases | |
CA2582247C (en) | 3-arylamino pyridine derivatives | |
JP5868386B2 (ja) | インドリルヒドロキサメート化合物又はインドリニルヒドロキサメート化合物 | |
JP2017061517A (ja) | キナーゼ調節のための化合物と方法、及びそのための適応 | |
WO2013134298A1 (en) | Raf inhibitor compounds | |
MX2011010065A (es) | Novedoso derivado de hidroxamato, un metodo de produccion del mismo y una composicion farmaceutica que comprende el mismo. | |
US20130102640A1 (en) | Method for the preparation of cis-1,2-diols in the kilogram scale | |
JP5133996B2 (ja) | 複素環ピリジルスルホンアミド誘導体、これらの製造方法、及び薬剤としての使用 | |
Deppe et al. | HAMILTON, BROOK, SMITH 4 REYNOLDS |